Deloitte China assists listing of Haixi Pharma on SEHK
Deloitte China supported the listing of Fujian Haixi Pharmaceuticals Co. Ltd - H Share (“Haixi Pharma”, Stock code: 02637.HK) on the Stock Exchange of Hong Kong (SEHK) on 20 October 2025.
Haixi Pharmaceuticals offered about 11.5 million shares at HKD86.40 each, raising around HKD 994 million.
(From left) Jason Pan, senior manager of Deloitte China's Strategy, Risk & Transactions; Tao Shuang, senior auditor of Audit & Assurance (A&A); Dean Chen, A&A manager; Lisa Li, Tax partner; Shirley Wang, A&A partner; Jeffrey Chung, Southern Region Offering Services partner of Capital Market Services Group; Ernest Lee, Deloitte China's Technical partner and a member of the Listing Committee of the SEHK; Feng Yan, Haixi Pharma's Executive Director and Deputy General Manager; Dr. Kang Xinshan, Haixi Pharma's Executive Director, Chairman of the Board and General Manager; David Yu, Deloitte China's A&A Chief Growth leader; Lawrence Lam, A&A partner; Vivien Bai, director of Central Business Development; Joey Tse, Siwen Jian and Tiffany Zhou, A&A senior auditors attend Haixi Pharm’s listing ceremony at Hong Kong Stock Exchange.
(From left) Dean Chen, Shirley Wang, Feng Yan, Dr. Kang Xinshan, Jeffrey Chung; and Zhang Junhuan, Finance Director and Secretary of the Board of Haixi Pharma attend Haixi Pharm’s listing ceremony at Hong Kong Stock Exchange.
Client overview
Haixi Pharma is pharmaceutical company that is in the commercial stage. It integrates the research and development, production and sales capacities, with a pipeline of innovative drug candidates in China. Its commercialized product portfolio primarily consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases.
As of 30 September 2025, Haixi Pharma had approval from the National Medical Products Administration for 15 generic drugs and established a pipeline of four innovative drug candidates.
Source: Haixi Pharma IPO prospectus published on 9 October 2025
Deloitte's role
As a core service institution of the IPO engagement, Deloitte China has been deeply involved in the entire process of offering reporting, fundraising and listing of the client, demonstrating Deloitte's professional service capabilities in serving clients in different, diverse capital markets.
In this engagement, our teams worked closely with various professional parties, provided high-quality services through its rich industry experience and excellent professional capabilities, and assisted the client to file the listing application to the SEHK.
Deloitte China congratulates Haixi Pharma on its successful listing on the SEHK. We will continue to provide high quality professional services and outstanding resources integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see About Deloitte to learn more.
Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.
We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.
The Deloitte brand originated in 1845, and its name in Chinese (德勤) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.
This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.
No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.
